PD-L1 Expression in Urothelial Carcinoma with Predominant or Pure Variant Histology: Concordance Among Three Commonly Used and Commercially Available Antibodies

The introduction of immune checkpoint blockade (ICB) therapy has transformed the management of advanced bladder cancer (BC). Despite its limitations, PD-L1 immunohistochemistry may serve as a predictive biomarker of anti-PD-L1/PD1 therapy. While urothelial carcinoma (UC) patients with predominant or...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Surg Pathol
Autores principales: Reis, Henning, Serrette, Rene, Posada, Jennifer, Lu, Vincent, Chen, Ying-bei, Gopalan, Anuradha, Fine, Samson W., Tickoo, Satish K., Sirintrapun, S. Joseph, Iyer, Gopa, Funt, Samuel A., Teo, Min Yuen, Rosenberg, Jonathan E., Bajorin, Dean F., Dalbagni, Guido, Bochner, Bernard H., Solit, David B., Reuter, Victor E., Al-Ahmadie, Hikmat A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561805/
https://ncbi.nlm.nih.gov/pubmed/31135485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAS.0000000000001264
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares